- Home
- IIPR vs CVAC Comparison
IIPR vs CVAC Comparison
Compare IIPR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIPR
- CVAC
- Stock Information
- Founded
- IIPR 2016
- CVAC 2000
- Country
- IIPR United States
- CVAC Germany
- Employees
- IIPR N/A
- CVAC N/A
- Industry
- IIPR Real Estate
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- IIPR Finance
- CVAC Health Care
- Exchange
- IIPR Nasdaq
- CVAC Nasdaq
- Market Cap
- IIPR 1.5B
- CVAC 1.2B
- IPO Year
- IIPR 2016
- CVAC 2020
- Fundamental
- Price
- IIPR $51.31
- CVAC $5.41
- Analyst Decision
- IIPR Hold
- CVAC Hold
- Analyst Count
- IIPR 8
- CVAC 3
- Target Price
- IIPR $88.75
- CVAC $6.83
- AVG Volume (30 Days)
- IIPR 261.3K
- CVAC 844.7K
- Earning Date
- IIPR 08-06-2025
- CVAC 08-14-2025
- Dividend Yield
- IIPR 14.79%
- CVAC N/A
- EPS Growth
- IIPR N/A
- CVAC N/A
- EPS
- IIPR 5.20
- CVAC 0.87
- Revenue
- IIPR $304,785,000.00
- CVAC $566,039,775.00
- Revenue This Year
- IIPR N/A
- CVAC N/A
- Revenue Next Year
- IIPR $0.94
- CVAC $24.04
- P/E Ratio
- IIPR $9.88
- CVAC $6.22
- Revenue Growth
- IIPR N/A
- CVAC 787.60
- 52 Week Low
- IIPR $45.44
- CVAC $2.37
- 52 Week High
- IIPR $138.35
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- IIPR 33.60
- CVAC 56.80
- Support Level
- IIPR $52.85
- CVAC $5.35
- Resistance Level
- IIPR $54.86
- CVAC $5.48
- Average True Range (ATR)
- IIPR 1.52
- CVAC 0.06
- MACD
- IIPR -0.22
- CVAC -0.04
- Stochastic Oscillator
- IIPR 13.27
- CVAC 42.86
About IIPR Innovative Industrial Properties Inc.
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.